Subjective Cognitive Decline (SCD)

Subjective cognitive decline names the state in which someone reports that their memory or thinking has worsened relative to a previous personal level, yet scores within the normal range on standardised cognitive tests. It was formalised as a research construct by an international working group in 2014, partly to standardise recruitment of a population described under a dozen inconsistent labels. In the staging of the Alzheimer's continuum it sits before mild cognitive impairment, defined by the absence of objective deficit.

It is common, reported by a substantial minority of older adults, and its prognostic value is real but weak: groups with subjective decline show higher rates of later progression than groups without, while most individuals within them never progress. The reason is that the complaint has many causes. Depression and anxiety, obstructive sleep apnoea, thyroid disease, vitamin B12 deficiency, anticholinergic and sedative burden, chronic pain and sleep debt all produce it, and each is more common and more treatable than neurodegeneration. Persistent post-viral cognitive complaints have added to the population under the informal heading of brain fog.

What the label should trigger is a search for reversible contributors and, in research, a decision about enrolment rather than a diagnosis. It also carries a methodological warning: a self-reported outcome in someone worried about their memory is among the most placebo-responsive endpoints in medicine, and expectation alone shifts it.

That is exactly why this population is a marketing target. Cognitive supplements and unapproved peptides are promoted to people whose defining feature is a subjective complaint with a normal objective test, so any perceived improvement is unfalsifiable, and open-label testimonials from that group carry no evidential weight.